CLINUVEL agrees with FDA on New Drug Application timelines
Filed with ASX · · 2 pages · English
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallClinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- SCENESSE - NICE England Update
- FDA Schedules Pre-NDA Meeting for SCENESSE
- Clinuvel completes combination therapy pre-clinical study
- FDA accept SCENESSE clinical data package for NDA submission
- FDA awards SCENESSE Fast Track designation for EPP treatment
Later from Clinuvel Pharmaceuticals
- CLINUVEL reaches agreement on German SCENESSE pricing
- NICE England Update on SCENESSE
- Amended Appendix 4C - quarterly
- Preliminary Final Report
- CLINUVEL provides update on SCENESSE FDA filing
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals